谷氨酸成像(GluCEST)显示精神病谱系患者脑内GluCEST对比度降低
研究采用7T MRI谷氨酸成像技术(GluCEST)比较精神病谱系患者(PS,n=19)与健康对照(HC,n=17)的皮层及皮层下谷氨酸水平。结果显示PS组皮层下(χ2(1)=4.65,P=0.031)和脑叶(χ2(1)=5.17,P=0.023)GluCEST对比度均低于HC组,且异常在临床高危(CHR,n=14)和精神分裂症(SZ,n=5)受试者中均可见,并与临床症状存在区域差异性相关。提示GluCEST对比度可能作为早期精神病标志物。
要点
- 精神病谱系患者皮层下和脑叶GluCEST对比度显著低于健康对照。
- GluCEST异常在临床高危和精神分裂症受试者中均存在。
- GluCEST对比度与临床症状的相关性因脑区而异。
核心结论
- 精神病谱系患者存在皮层下和脑叶GluCEST对比度降低,提示谷氨酸能系统异常早期即出现。
- GluCEST对比度异常在临床高危和精神分裂症受试者中均可见,并与临床症状区域差异性相关。
- GluCEST方法有望作为早期精神病神经化学标志物并帮助阐明疾病进展。
研究设计与样本
- 研究纳入精神病谱系患者(PS,n=19)和健康年轻个体(HC,n=17),均接受3T和7T MRI成像。
- 在7T下采用单层GluCEST技术估计在体谷氨酸水平。
- 比较皮层下、额叶、顶叶和枕叶的GluCEST对比度,并分析其与临床症状的相关性。
主要发现
- PS组皮层下GluCEST对比度低于HC组(χ2(1)=4.65,P=0.031)。
- PS组脑叶GluCEST对比度低于HC组(χ2(1)=5.17,P=0.023)。
- 异常GluCEST对比度在CHR(n=14)和SZ(n=5)受试者中均可见,且与临床症状存在区域差异性相关。
关键数值与推荐
- 皮层下GluCEST对比度组间比较:χ2(1)=4.65,P=0.031。
- 脑叶GluCEST对比度组间比较:χ2(1)=5.17,P=0.023。
临床怎么用
- GluCEST成像可用于评估精神病谱系患者皮层及皮层下谷氨酸水平异常。
- GluCEST对比度异常可能有助于识别早期精神病高风险个体。
- 区域特异性GluCEST对比度与症状的相关性提示其潜在临床标记价值。
局限性
- 样本量较小(PS组n=19,HC组n=17),结果需更大样本验证。
- 采用单层GluCEST技术,空间覆盖有限。
- GluCEST对比度反映谷氨酸贡献但非直接绝对浓度测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psychosis commonly develops in adolescence or early adulthood. Youths at clinical high risk (CHR) for psychosis exhibit similar, subtle symptoms to those with schizophrenia (SZ). Malfunctioning neurotransmitter systems, such as glutamate, are implicated in the disease progression of psychosis. Yet, in vivo imaging techniques for measuring glutamate across the cortex are limited. Here, we use a novel 7 Tesla MRI glutamate imaging technique (GluCEST) to estimate changes in glutamate levels across cortical and subcortical regions in young healthy individuals and ones on the psychosis spectrum. Individuals on the psychosis spectrum (PS; n=19) and healthy young individuals (HC; n=17) underwent MRI imaging at 3 and 7 T. At 7 T, a single slice GluCEST technique was used to estimate in vivo glutamate. GluCEST contrast was compared within and across the subcortex, frontal, parietal and occipital lobes. Subcortical (χ2 (1)=4.65, P=0.031) and lobular (χ2 (1)=5.17, P=0.023) GluCEST contrast levels were lower in PS compared with HC. Abnormal GluCEST contrast levels were evident in both CHR (n=14) and SZ (n=5) subjects, and correlated differentially, across regions, with clinical symptoms. Our findings describe a pattern of abnormal brain neurochemistry early in the course of psychosis. Specifically, CHR and young SZ exhibit diffuse abnormalities in GluCEST contrast attributable to a major contribution from glutamate. We suggest that neurochemical profiles of GluCEST contrast across cortex and subcortex may be considered markers of early psychosis. GluCEST methodology thus shows promise to further elucidate the progression of the psychosis disease state.
引用
- Roalf DR, Nanga RPR, Rupert PE, et al. Glutamate imaging (GluCEST) reveals lower brain GluCEST contrast in patients on the psychosis spectrum. Mol Psychiatry. 2017. PMID: 28115738. doi:10.1038/mp.2016.258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。